Biogen Idec U.S. Corp. v. Blanton

20 Mass. L. Rptr. 290
CourtMassachusetts Superior Court
DecidedNovember 21, 2005
DocketNo. 05399
StatusPublished

This text of 20 Mass. L. Rptr. 290 (Biogen Idec U.S. Corp. v. Blanton) is published on Counsel Stack Legal Research, covering Massachusetts Superior Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Biogen Idec U.S. Corp. v. Blanton, 20 Mass. L. Rptr. 290 (Mass. Ct. App. 2005).

Opinion

Hines, Geraldine S., J.

INTRODUCTION

The plaintiff, Biogen Idee U.S. Corporation (“Bio-gen”), brought an action before this Court for a declaratory judgment that the laws of the Commonwealth of Massachusetts govern the terms of Lisa Blanton’s employment and termination of employment with Biogen. Biogen’s declaratory judgment complaint also seeks an order from this Court declaring that Biogen did not: (1) wrongfully terminate Blanton’s employment in violation of Massachusetts common law; (2) violate the Sarbanes-Oxley Act; (3) retaliate against Blanton for any protected whistle-blowing activity; (4) discriminate or retaliate against her on the basis of her gender or complaints about gender discrimination in violation of Massachusetts common law; or (5) engage in any other conduct towards Blanton violating any other statutory or common law.

Blanton has filed an anti-SLAPP (Strategic Litigation Against Public Participation) special motion to dismiss Biogen’s declaratory judgment complaint pursuant to G.L.c. 231, §59H. Blanton has met her threshold burden required for a special motion to dismiss pursuant to G.L.c. 231, §59H. In addition, Biogen has failed to meet its burden to show, by pleadings and affidavits, and by a preponderance of the evidence, that (1) Blanton’s petitioning activities were devoid of any reasonable factual support or any arguable basis of law and (2) Blanton’s acts caused actual injury to Biogen. G.L.c. 231, §59H. Accordingly, for the reasons set forth below, Blanton’s special motion to dismiss is ALLOWED.

BACKGROUND

Biogen is a Massachusetts corporation with its principal place of business in Cambridge, Massachusetts. In April 1997, Biogen hired Blanton as a National Accounts Manager. In October 2002, Blanton accepted the position of Associate Director, Medicare, in the National Accounts Department. Biogen contends that as part of her employment, Blanton signed a “Noncompetition, Nonsolicitation, and Nondisclosure Agreement” (“the nondisclosure agreement”) on or about April 12, 2002. The nondisclosure agreement contains a provision stating that any employment action by Blanton against the company is governed by the laws of the Commonwealth of Massachusetts.

Blanton primarily worked out of her home office in Ohio. Although Blanton traveled throughout the United States in the course of her employment with Biogen, the company argues that to the extent any location other than Blanton’s home office was her primary place of employment, that location was Biogeris world headquarters in Cambridge, Massachusetts. Biogen contends that most of Blanton’s supervisors reside near the company’s Massachusetts headquarters and most of the company’s personnel records, human resource functions, and documents are maintained in Cambridge.

Biogen argues that on or about January 8, 2004, the company posted an opening for the position of Director [291]*291of National Accounts and that the posting remained open until January 15, 2004, as per Biogen policy. The company contends that Blanton never applied or formally expressed an interest in the position. Blanton claims that the company passed her over for the position and instead hired a less-qualified male. On June 10, 2004, Blanton filed an EEOC gender discrimination charge in Ohio. The EEOC transferred the matter to its Boston office and cross-filed with the MCAD. From September 25, 2004 through December 31, 2004, Blanton was on leave under the Family Medical Leave Act (“FMLA’j. On December 22, 2004, the MCAD issued a letter to Biogen advising the company of the EEOC and MCAD charge. Blanton was terminated on December 28, 2004.

Blanton sent a demand letter to Biogen on January 28, 2005. The demand letter set forth multiple claims against the company, including violations of G.L.c. 15 IB, the Sarbanes-Oxley Act of2002, the Family and Medical Leave Act, and the District of Columbia Human Rights Act. The letter set out terms for settlement and indicated that if a response was not received from Biogen by February 9, 2005, Blanton would initiate legal action. On February 4, 2005, Biogen filed its complaint for declaratoryjudgment with this Court. On February 15, 2005 and February 18, 2005, respectively, Blanton filed complaints with the Department of Labor (“DOL”) and the United States District Court for the District of Columbia (D.C. District Court).

DISCUSSION

I. Special Motion to Dismiss Pursuant to G.L.c. 231, §59H

The Massachusetts Anti-SLAPP Statute, G.L.c. 231, §59H, was passed to protect individual citizens from lawsuits designed to chill their right of petitioning and free speech. The statute sets out in relevant part that “(i]n any case in which a party asserts that the civil claims against said party are based on said party’s exercise of its right to petition under the constitution of the United States or of the commonwealth, said party may bring a special motion to dismiss.” Id. As the Supreme Judicial Court described:

The objective of SLAPP suits is not to win them, but to use litigation to intimidate opponents’ exercise of rights of petitioning and speech. SLAPP suits target people for “reporting violations of law, writing to government officials, attending public hearings, testifying before government bodies, circulating petitions for signature, lobbying for legislation, campaigning in initiative or referendum elections, filing agency protests or appeals, being parties in law-reform lawsuits, and engaging in peaceful boycotts and demonstrations.”

Duracraft Corp. v. Holmes Prods. Corp., 427 Mass. 156, 161-62 (1998) (internal citations omitted). The act itself broadly defines the right to petition as:

any written or oral statement made before or submitted to a legislative, executive, or judicial body, or any other governmental proceeding; any written or oral statement made in connection with an issue under consideration or review by a legislative, executive, or judicial body, or any other governmental proceeding; any statement reasonably likely to encourage consideration or review of an issue by a legislative, executive, or judicial body or any other governmental proceeding; any statement reasonably likely to enlist public participation in an effort to effect such consideration; or any other statement falling within the constitutional protection of the right to petition the government.

G.L.c. 231, §59H.

A. The Burden on the Moving Party Under G.L.C. 231, §59H

Under G.L.c. 231, §59H, the moving party is required to make a prima facie showing that she is exercising her right to petition. Formerly, this was all the showing the moving party needed to make to cause the burden of production to then shift to the non-moving party. The non-moving party was then required to show that the moving party’s exercise of her right to petition was (1) devoid of any reasonable factual support or any arguable basis in law and (2) caused actual injury to the non-moving party. G.L.c. 231, §59H. Under this earlier standard, there was a question of whether the anti-SLAPP legislation was intended to authorize the dismissal of an otherwise valid claim. If the anti-SLAPP legislation did so authorize such dismissals, then it would impair the constitutionally protected right to petition a court or some other governmental body with such authority" for redress of a grievance.

The Duracraft

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Duracraft Corp. v. Holmes Products Corp.
691 N.E.2d 935 (Massachusetts Supreme Judicial Court, 1998)
Ayasli v. Armstrong
780 N.E.2d 926 (Massachusetts Appeals Court, 2002)
Garabedian v. Westland
796 N.E.2d 439 (Massachusetts Appeals Court, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
20 Mass. L. Rptr. 290, Counsel Stack Legal Research, https://law.counselstack.com/opinion/biogen-idec-us-corp-v-blanton-masssuperct-2005.